Top Markets
#1 TENDIES TENDIES +46.01%
#2 Cash Cat Cash Cat +32.68%
#3 Threshold Network Threshold Network +29.49%
#4 Asteroid Shiba Asteroid Shiba +17.55%
#5 OSK OSK +15.83%
#6 Ape and Pepe Ape and Pepe +12.62%
#7 MarsCoin MarsCoin +11.53%
#8 Kite Kite +9.63%
#9 Ardor Ardor +9.02%
#10 Magma Finance Magma Finance +8.80%
Coin of the day
TENDIES TENDIES
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660
Classifica tra le azioni #16674
Operating within the People's Republic of China, AIM Vaccine Co., Ltd.... Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Prezzo delle azioni
$0.23346537
Capitalizzazione di mercato
$285.87M
Variazione (1 giorno)
6.41%
Variazione (1 anno)
-63.91%
Paese
CN
Scambia AIM Vaccine Co., Ltd. (6660)

Categoria

Healthcare
Margine operativo per AIM Vaccine Co., Ltd. (6660)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di AIM Vaccine Co., Ltd., il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per AIM Vaccine Co., Ltd. da 2026 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
Non abbastanza dati per le date fornite.
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.